Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.
Oxygen is essential
for life.
The constant uptake and delivery of oxygen within our body is necessary to sustain life in sickness and in health, under stress or at rest.
Founded in 2001, our mission is to enhance the standard-of-care treatment for conditions associated with hypoxia, a potentially fatal shortage of oxygen in tissue and a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.
Recent Milestones
FEB 2021
Announced completion of $34.5 in financing
FEB & MAY 2021
Announced data from COVID 303 study
MAR 2021
Completed enrollment and dosing in TCOM study
JUNE 2021
Reported topline data from TCOM study
JUNE 2021
Appointed new board chair and two new directors
2Q 2021
Added new employees to enhance operating team
3Q 2021
Initiate Altitude study
4Q 2021
Initiate ILD-DLCO study
4Q 2021
Report topline data from Altitude study
1Q 2022
Report topline data from ILD-DLCO study
1Q 2022
Initiate study in to-be-specified indication
Our lead product candidate, Trans sodium crocetinate (TSC), is a first-in-class, small molecule therapeutic with a novel mechanism-of-action that enhances the diffusion of oxygen to hypoxic tissues.
TSC would be the first therapy specifically designed to enhance the oxygen diffusion process, thereby supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points. In animal models, this diffusion-enhancing mechanism-of-action has been observed to affect hypoxic tissue preferentially while avoiding excessive oxygen-related tissue toxicity, also known as hyperoxia.
TSC has been observed to be safe and well-tolerated at most doses tested in over 200 subjects included to-date in our clinical studies.
The company’s second pipeline asset, DFN-529, is a novel, allosteric PI3K/Akt/mTOR pathway inhibitor. Two Phase 1 clinical trials have been completed evaluating DFN-529 in age-related macular degeneration and preclinical studies have been performed in preclinical models of glioblastoma multiforme (GBM).